×
About 880 results

ALLMedicine™ Intestinal Perforation Center

Research & Reviews  323 results

Surge of Typhoid Intestinal Perforations as Possible Result of COVID-19-Associated Dela...
https://doi.org/10.3201/eid2712.210516
Emerging Infectious Diseases; Jeon HJ, Marks F et. al.

Nov 23rd, 2021 - During the coronavirus disease pandemic, we observed a 6.4-fold increase in typhoid intestinal perforation incidence in Antananarivo, Madagascar. Thirteen perforations occurred within 6 months (February 2020-July 2020), compared with 13 perforatio...

The diagnosis and treatment of retrograde intussusception: a single-centre experience.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590751
BMC Surgery; Zhang B, Wu D et. al.

Nov 15th, 2021 - To investigate the clinical manifestations, treatments of retrograde intussusception and summarize the experience. Children with retrograde intussusception treated in our hospital from January 2011 to January 2021 were retrospectively analysed. De...

COVID 19 and the risk of gastro-intestinal perforation: A case series and literature re...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562067
Journal of Critical Care; Bulte JP, Postma N et. al.

Nov 7th, 2021 - COVID19 is a viral disease with pneumonia as its most common presentation. Many presentations and complications have been reported, but gastro-intestinal perforation has not received much attention. three cases from our hospital are presented, and...

Monomorphic epitheliotropic intestinal T-cell lymphoma presenting as melena with long-t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517785
World Journal of Gastroenterology; Ozaka S, Inoue K et. al.

Nov 2nd, 2021 - Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare primary intestinal T-cell lymphoma, previously known as enteropathy-associated T-cell lymphoma type II. MEITL is an aggressive T-cell lymphoma with a poor prognosis and high ...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  7 results

Noninferiority Trial of Liquid Human Milk Fortifier (HMF) Hydrolyzed Protein Versus Liquid HMF With Supplemental Liquid Protein
https://clinicaltrials.gov/ct2/show/NCT03001479

Jun 18th, 2021 - All infants admitted to the Neonatal Intensive Care Unit (NICU) at Cardinal Glennon at gestational age <32 weeks and birthweight <1500g, and whose mothers intend to use breast milk (maternal or donor) will be approached for study participation. In...

The Basel Enteral High Protein Study
https://clinicaltrials.gov/ct2/show/NCT02678325

Mar 30th, 2021 - For years, the Surgical Intensive Care Unit of the University Hospital Basel has used an early enteral approach for the feeding of critically ill patients with different formulas that have high protein content (20% of total energy). However, the e...

Is TIme From adMission to surgEry an Independent Prognostic Factor for Survival of Patients With Gastro-intestinal Perforation Associated With Septic Shock: (TIME) An Italian Intersocietary Retrosp...
https://clinicaltrials.gov/ct2/show/NCT04811755

Mar 23rd, 2021 - This is an Italian National multicenter study composed by a retrospective phase of data collection from patients of past ten years and a perspective one of next two years. INCLUSION AND EXCLUSION CRITERIA We include in our analysis all patients wi...

NETs: Protection or Harm in Neonatal Inflammation or Infection
https://clinicaltrials.gov/ct2/show/NCT00747851

Feb 5th, 2020 - Many pediatric diseases including Systemic Inflammatory Response Syndrome (SIRS), sepsis, Acute Respiratory Distress Syndrome (ARDS) and neonatal Chronic Lung Disease (CLD) have been associated with dysregulation of the acute inflammatory response...

Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part IV
https://clinicaltrials.gov/ct2/show/NCT01604447

Feb 24th, 2015 - Due to limited resources and numbers of incubators, hospitals in developing countries remove infants from incubators at lower weights than in developed countries, putting infants at increased risk for hypothermia. This study will compare the incid...

see more →

News  21 results

Idelalisib Use Expands With New CLL Indication Pending
https://www.onclive.com/view/idelalisib-use-expands-with-new-cll-indication-pending

Oct 6th, 2021 - Jeffrey A. Jones, MD, MPH The utilization of idelalisib (Zydelig) increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting, according to Gilead Sciences, the developer of...

Preemies' Blood Type Tied to Risk for Serious Intestinal Infections
https://www.medpagetoday.com/gastroenterology/generalgastroenterology/93461

Jul 7th, 2021 - AB blood type was associated with a higher risk for necrotizing enterocolitis (NEC) and focal intestinal perforation (FIP) in preterm infants, as compared with other blood types, a German population-based study found. Among very low birth weight i...

Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer
https://www.onclive.com/view/prolonged-treatment-with-bevacizumab-does-not-yield-further-survival-benefit-in-ovarian-cancer

Jun 7th, 2021 - Although prolonged treatment with bevacizumab (Avastin) for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the s...

Lenvatinib and Pembrolizumab Combination Safe, Effective For Multiple Gastrointestinal Cancer Types
https://www.onclive.com/view/lenvatinib-and-pembrolizumab-combination-safe-effective-for-multiple-gastrointestinal-cancer-types

Jan 15th, 2021 - The combination of the anti-angiogenic multikinase inhibitor lenvatinib (Lenvima) plus the anti-PD-1 antibody pembrolizumab (Keytruda) demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with ad...

Singal Speaks to ASCO Highlights in Rapidly Evolving HCC Paradigm
https://www.onclive.com/view/singal-speaks-to-asco-highlights-in-rapidly-evolving-hcc-paradigm

Dec 20th, 2020 - The treatment landscape of advanced hepatocellular carcinoma (HCC) has been subject to rapid development in the last few years, said Amit G. Singal, MD, MS, who added that the introduction of novel agents is particularly encouraging given the dark...

see more →